Figure 4

VE-Cad+ derived cells show decrease contribution to endothelium and neo-angiogenesis in Cll-treated mice. (a) Representative images of cross-sections TA muscle immunostained for EYFP (green) and CD31 (red) from sham- and Cll-treated Cdh5-CreERT2;R26R-EYFP mice 10 days after CTX. Magnification × 20. Scale bar: 50 μm. (b) Quantification of β-Gal+CD31+ and β-Gal+CD31− cells measured as the percentage of positive cells on the total β-Gal+ cells per square millimeter in immunostained TA muscle sections from sham- and Cll-treated Cdh5-CreERT2; R26R- NZG mice, 5, 7, 10, 15 days after CTX injection. Data are expressed as means±S.E.M. (n=3). Statistically significant differences are indicated (sham versus Cll *P<0.05)